Ramius

Manufacturer of engineered components intended for the aerospace and defense, marine, nuclear as well as oil and gas industries. The company offers lead and bronze engineered products, complex precision-engineered components as well as nuclear shielding, containment and remote handling equipment, providing clients with reliable mission-critical products.

NJOY, Inc. is an American company that specializes in the manufacture and distribution of electronic cigarette products aimed at adult smokers. Founded in 2006 and headquartered in Scottsdale, Arizona, NJOY offers a range of products, including non-rechargeable electronic cigarette packs, rechargeable starter kits, disposable electronic cigarettes, and various accessories like chargers and batteries. The company positions itself as a pioneer in the vaping industry, advocating for alternatives to combustible cigarettes. NJOY's products are available nationwide, marketed through online platforms and a network of retail and convenience stores across the United States. With additional offices in New York City, NJOY continues to innovate within the rapidly growing vaping market.

Bluebird Bio is a clinical-stage biotechnology company focused on developing transformative gene therapies for severe genetic diseases and cancer. The company is engaged in researching and commercializing therapies that aim to genetically modify patients' cells to correct the underlying genetic causes of diseases. Key programs include LentiGlobin for β-thalassemia and sickle cell disease, and Lenti-D for cerebral adrenoleukodystrophy. In oncology, bluebird bio is developing CAR T cell therapies, such as bb2121 and bb21217, for multiple myeloma. The company has formed strategic collaborations with Bristol-Myers Squibb and Regeneron Pharmaceuticals to advance gene therapies in oncology, and works with various partners to develop innovative solutions in cancer treatment and in vivo genome editing for genetic disorders. Founded in 1992 and headquartered in Cambridge, Massachusetts, bluebird bio generates revenue through collaboration arrangements, research fees, license fees, and grants.

Cascadian Therapeutics, a clinical-stage biopharmaceutical company, researches and develops, and sells therapeutic products for the treatment of cancer in the United States. The company lead clinical-stage product candidate is tucatinib, an orally active and HER2-selective small molecule tyrosine kinase inhibitor, which is in two Phase Ib trials, one in combination with Kadcyla and another in combination with Xeloda and/or Herceptin. It is also developing Checkpoint kinase 1, a protein kinase that is in pre-clinical studies to regulate the cell division cycle, as well as to DNA damage and replication stress. In addition, the company focuses on the development of novel antibodies and T-cell immunoreceptor with Ig and ITM domains, an inhibitory receptor expressed on T-cells and NK cells that negatively regulate immune response to cancers. It has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize tucatinib; research collaboration agreement with Sentinel Oncology Ltd. for the discovery of novel Chk1 inhibitors; and collaboration agreement with Adimab LLC for the discovery of novel antibodies against d immunotherapy targets in oncology.

Biomoda, Inc. is a development stage company based in Albuquerque, New Mexico, focused on in-vitro diagnostics, particularly in the detection of cancer. The company is advancing its key product, CyPath, an assay designed to identify early-stage lung cancer through a non-invasive method. This diagnostic test utilizes a patented porphyrin application that selectively binds to cancerous cells in deep-lung sputum samples. In addition to lung cancer, Biomoda is exploring diagnostic protocols for other types of cancer, including breast and prostate cancer. The company collaborates with the New Mexico Institute of Mining and Technology for clinical studies aimed at early lung cancer detection among veterans. Furthermore, Biomoda has partnered with Medical Acoustics, LLC for the use of its Lung Flute device in sample collection, and has secured consulting agreements to navigate the FDA approval process. Founded in 1990, Biomoda is committed to developing innovative solutions for cancer detection.

SinoHub, Inc. is an electronics company based in Shenzhen, China, that operates globally through two main segments: Integrated Contract Manufacturing (ICM) and Electronic Component Sales and Services (ECSS). The ICM segment specializes in the production of custom, private label mobile phones and tablets. In contrast, the ECSS segment focuses on the sale of electronic components to manufacturers and design houses, along with providing supply chain management services such as warehousing, logistics, and import/export operations. SinoHub also offers a proprietary web-based software platform that streamlines the procurement and management of electronic components, facilitating order tracking, inventory management, and vendor oversight. Founded in 2000, SinoHub serves a diverse clientele, including contract manufacturers, original equipment manufacturers (OEMs), and electronics manufacturing services (EMS) companies, enhancing their efficiency in the competitive electronics market.

CEL-SCI Corporation, founded in 1983 and headquartered in Vienna, Virginia, focuses on the research and development of immunotherapy products to treat cancer and infectious diseases. The company's leading investigational therapy, Multikine, is currently undergoing phase III clinical trials for head and neck cancer. Additionally, CEL-SCI has developed a patented T-cell modulation process known as the Ligand Epitope Antigen Presentation System (LEAPS), which aims to enhance the immune response against a range of health issues, including bacterial, viral, and parasitic infections, as well as autoimmune diseases and allergies. The company is also working on LEAPS-H1N1-DC, CEL-2000, and CEL-4000 for rheumatoid arthritis, alongside LEAPS COV-19 to address COVID-19. CEL-SCI has partnered with the University of Georgia’s Center for Vaccines and Immunology to advance its COVID-19 immunotherapy initiatives.

BravoSolution SpA specializes in supply management technology software and services tailored for procurement and sourcing applications. The company provides a comprehensive suite of solutions that includes spend analysis to enhance savings and compliance, eSourcing for collaborative sourcing efforts, supplier performance management, and contract management to streamline contract processes. Additionally, BravoSolution offers cloud-based tools such as BravoAlign for procurement alignment and transformation, and BravoAdvantage, which supports organizations in generating procurement initiatives from demand to contract. Their analytics platform, BravoAdvantage Analytics, allows procurement professionals to visualize data and create intuitive reports for stakeholders. BravoSolution also delivers collaboration services across various sectors, including transportation and temporary labor, as well as government solutions focused on spend visibility and electronic sourcing. Founded in 2000 and headquartered in Milan, Italy, BravoSolution operates additional offices globally and is a subsidiary of JAGGAER, Inc.

EarlyBirdCapital, Inc. is a boutique investment banking firm established in 2000 and located in New York City. The firm specializes in providing financial services to smaller capitalization companies and has developed significant expertise in Special Purpose Acquisition Companies (SPACs). EarlyBirdCapital is involved in a variety of investment banking activities, including equity offerings, private placements, public offerings, mergers and acquisitions, debt placements, fairness opinions, valuations, and recapitalization transactions. As a registered broker-dealer and member of various regulatory bodies, the firm serves as an underwriter for SPAC initial public offerings, reflecting its focus on innovative financial solutions within the investment landscape.

ci4net.com is a European economic network, or "Econet". The Company currently owns 50% or more of 26 Internet companies involved in Business-to-Business, Business-to-Consumer, e-Commerce and infrastructure. ci4net.com is focused on adding value at all stages of a company's development via its network. ci4net.com can provide infrastructure technologies, operational and management resources and synergistic access to a network of portfolio companies.

Xceed has been creating top-of-the-line software components for nearly 20 years. Their current product line boasts over 135 professional components, which are used by more than 100,000 professional developers worldwide, including Microsoft in applications such as Visual Studio 2010 and 2012 and Microsoft Office. Their focus is on creating and marketing UI controls that help developers and designers create a compelling user experience (UX) with the Windows Presentation Foundation (WPF), the backbone of LOB solutions. Xceed DataGrid for WPF is their flagship product. Their extensive offering also includes some of the most popular UI controls and data manipulation libraries for .NET (such as Zip and FTP), as well as controls and libraries for Silverlight, Windows Phone, and ActiveX/COM.